DelveInsight’s, “Untreated Metastatic or Unresectable Melanoma Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Untreated Metastatic or Unresectable Melanoma pipeline landscape. It covers the Untreated Metastatic or Unresectable Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Untreated Metastatic or Unresectable Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Untreated Metastatic or Unresectable Melanoma Treatment Drugs @ https://www.delveinsight.com/sample-request/untreated-metastatic-or-unresectable-melanoma-pipeline-insight
Key Takeaways from the Untreated Metastatic or Unresectable Melanoma Pipeline Report
- On January 2026- mAbxience Research S.L. conducted a study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma
- DelveInsight’s Untreated Metastatic or Unresectable Melanoma Pipeline analysis depicts a robust space with 10+ Untreated Metastatic or Unresectable Melanoma companies working to develop 10+ pipeline treatment therapies.
- The leading Untreated Metastatic or Unresectable Melanoma Companies such as Biocad, Ultimovacs ASA, Anaveon AG, BioNTech US Inc., Iovance Biotherapeutics, Inc., MacroGenics, Targovax Oy, Istari Oncology, Inc., Scancell Ltd, Takara Bio Inc., Turnstone Biologics, Corp., Amgen, Multitude Therapeutics Inc. and others.
- Promising Untreated Metastatic or Unresectable Melanoma Pipeline Therapies such as Cylembio, Fianlimab, Lifileucel, EVX-01, EIK1001, V940 (mRNA-4157), Brenetafusp, and others
Find out more about Untreated Metastatic or Unresectable Melanoma Therapeutics Assessment @ Untreated Metastatic or Unresectable Melanoma Preclinical and Discovery Stage Products
The Untreated Metastatic or Unresectable Melanoma Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Untreated Metastatic or Unresectable Melanoma Pipeline Report also highlights the unmet needs with respect to the Untreated Metastatic or Unresectable Melanoma.
Untreated Metastatic or Unresectable Melanoma Overview
Metastatic or unresectable melanoma is an advanced stage of skin cancer where the malignant cells have spread from the primary site to other parts of the body or cannot be surgically removed. Melanoma originates in melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. When melanoma progresses to a metastatic or unresectable stage, it significantly impacts prognosis and requires a more complex treatment approach. The signs and symptoms of metastatic melanoma vary depending on the organs involved. Common symptoms include persistent skin changes such as new growths, sores that do not heal, changes in existing moles (size, shape, color, or feel), and pigmentation spreading beyond the border of a mole. Symptoms specific to metastasis might include swollen lymph nodes, weight loss, fatigue, pain or tenderness in the bones, persistent cough or trouble breathing, and neurological symptoms if the brain is affected.
Untreated Metastatic or Unresectable Melanoma Emerging Drugs
- Prolgolimab: Biocad
Prolgolimab is an IgG1 anti–PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing ‘LALA’ mutation. The drug candidate is designed to restore the anti-tumor activity of the human body’s immune response. The Ministry of Health of the Russian Federation has authorized a Russian originator drug for the treatment of unresectable or metastatic melanoma. The product was developed by BIOCAD, a biotechnology company; it is a fixed dose combination of two monoclonal antibodies, nurulimab and prolgolimab. The product will be marketed under the trade name Nurdati®. It is based on a 1:3 fixed dose combination of originator anti-CTLA-4 (nurulimab) and anti-PD-1 (prolgolimab) monoclonal antibodies. The product enhances the immune system capability of combating the tumor. Combining nurulimab and prolgolimab in the product promotes T cell activation at various stages of the immune response so they are able to recognize and destroy malignant cells. In other words, antitumor immunological surveillance is triggered and the body starts fighting against the malignant neoplasm. Currently, the drug is in Phase III stage of its development for the treatment of unresectable metastatic melanoma.
- UV1: Ultimovacs ASA
UV1 is an off-the-shelf therapeutic cancer vaccine designed to induce a specific T cell response against telomerase. UV1 consists of long, synthetic peptides representing a sequence in the reverse transcriptase subunit of telomerase (hTERT), shown to induce CD4+ T cells. These CD4+ T cells have the potential to provide inflammatory signals and T cell support believed to be critical for triggering a strong anti-tumor immune response. The UV1 peptides contain several epitopes, shown to be non-restrictive in terms of (HLA) alleles for presentation. It is therefore not required to perform HLA pre-screening of patients, which potentially enables broad population utilization of the vaccine. UV1 is administered over three months with eight intradermal injections and the immune-modulator GM-CSF. In February 2024, US FDA granted Fast Track designation to UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall survival, including first-line patients. Currently, the drug is in Phase II stage of its development for the treatment of unresectable metastatic melanoma.
- ANV419: Anaveon AG
ANV419 is a powerful and selective IL-2 agonist, in patients with solid tumors which has been specifically designed to enable the delivery of high dose IL-2 to patients, with a favourable safety and tolerability profile. As of the data cut-off of 31 March 2023, 40 adult patients with advanced solid tumors and progression after =1 previous lines of systemic therapy were enrolled and received at least one dose of ANV419. The monotherapy was delivered as an intravenous infusion once every 2 weeks at doses up to 364 µg/kg. ANV419 was generally well tolerated, and drug-related adverse events were manageable, reversible, and responsive to supportive care therapy. ANV419 was generally well tolerated, and drug-related adverse events were manageable, reversible, and responsive to supportive care therapy. Currently, the drug is in Phase II stage of its development for the treatment of unresectable or metastatic melanoma.
- BNT221: BioNTech US Inc.
BNT221 is a personal neoantigen-targeting T cell therapy candidate derived from patients’ peripheral blood cells (PBMC). The product candidate consists of multiple CD8+ and CD4+ T cell populations targeting multiple selected neoantigens unique to each patient’s tumor. The proprietary stimulation process allows for the induction of T cells from the naïve as well as expansion of T cells from the memory compartment of the immune system. BNT221 is currently being evaluated in a first-in-human Phase I trial in patients with advanced unresectable or metastatic melanoma. Initial results show a manageable safety profile with no dose limiting toxicities and tumor regression in several patients with anti-PD-1 and anti-CTLA-4 pretreated advanced or metastatic melanoma.
Don’t miss this opportunity to stay informed—download now! @ Untreated Metastatic or Unresectable Melanoma Treatment Drugs
The Untreated Metastatic or Unresectable Melanoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Untreated Metastatic or Unresectable Melanoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Untreated Metastatic or Unresectable Melanoma Treatment.
- Untreated Metastatic or Unresectable Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Untreated Metastatic or Unresectable Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Untreated Metastatic or Unresectable Melanoma market.
Untreated Metastatic or Unresectable Melanoma Companies
Biocad, Ultimovacs ASA, Anaveon AG, BioNTech US Inc., Iovance Biotherapeutics, Inc., MacroGenics, Targovax Oy, Istari Oncology, Inc., Scancell Ltd, Takara Bio Inc., Turnstone Biologics, Corp., Amgen, Multitude Therapeutics Inc. and others.
Untreated Metastatic or Unresectable Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Untreated Metastatic or Unresectable Melanoma Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging Untreated Metastatic or Unresectable Melanoma Pipeline Therapies @ Untreated Metastatic or Unresectable Melanoma Clinical Trials Assessment
Scope of the Untreated Metastatic or Unresectable Melanoma Pipeline Report
- Coverage- Global
- Untreated Metastatic or Unresectable Melanoma Companies- Biocad, Ultimovacs ASA, Anaveon AG, BioNTech US Inc., Iovance Biotherapeutics, Inc., MacroGenics, Targovax Oy, Istari Oncology, Inc., Scancell Ltd, Takara Bio Inc., Turnstone Biologics, Corp., Amgen, Multitude Therapeutics Inc. and others.
- Untreated Metastatic or Unresectable Melanoma Pipeline Therapies- Cylembio, Fianlimab, Lifileucel, EVX-01, EIK1001, V940 (mRNA-4157), Brenetafusp, and others
- Untreated Metastatic or Unresectable Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Untreated Metastatic or Unresectable Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download now to stay at the forefront of pharmaceutical innovation!” @ Untreated Metastatic or Unresectable Melanoma Emerging Drugs and Companies
Table of Contents
1. Introduction
2. Executive Summary
3. Untreated Metastatic or Unresectable Melanoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Untreated Metastatic or Unresectable Melanoma Pipeline Therapeutics
6. Untreated Metastatic or Unresectable Melanoma Pipeline: Late-Stage Products (Phase III)
7. Untreated Metastatic or Unresectable Melanoma Pipeline: Late-Stage Products (Phase III)
8. Untreated Metastatic or Unresectable Melanoma Pipeline: Mid-Stage Products (Phase II)
9. Untreated Metastatic or Unresectable Melanoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
